May 12 (Reuters) - GENFIT SA:
* ANNOUNCED ON MONDAY INTERIM ANALYSIS OF RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR DID NOT DEMONSTRATE SIGNIFICANT EFFECT ON PRIMARY ENDPOINT OF NASH RESOLUTION WITHOUT WORSENING OF FIBROSIS
* RESPONSE RATE IN THE 717 PATIENTS ENROLLED ON STUDY DRUG WAS 19.2% FOR PATIENTS WHO RECEIVED ELAFIBRANOR 120MG COMPARED TO 14.7% FOR PATIENTS IN THE PLACEBO ARM
* ON THE FIBROSIS KEY SECONDARY ENDPOINT, 24.5% OF PATIENTS WHO RECEIVED ELAFIBRANOR 120MG ACHIEVED FIBROSIS IMPROVEMENT OF AT LEAST ONE STAGE COMPARED TO 22.4% IN THE PLACEBO ARM
* THE OTHER KEY SECONDARY ENDPOINT RELATED TO METABOLIC PARAMETERS DID NOT ACHIEVE STATISTICAL SIGNIFICANCE
* SAFETY AND TOLERABILITY OF ELAFIBRANOR WAS CONSISTENT WITH PREVIOUSLY CONDUCTED STUDIES
* WE PLAN TO SHARE THESE DETAILED FINDINGS WITH THE REGULATORY AUTHORITIES IN THE COMING MONTHS AND, WITH THEIR GUIDANCE, DETERMINE A FINAL DECISION REGARDING THE CONTINUATION OF THE RESOLVE-IT TRIAl - CEO
* WILL ENGAGE WITH REGULATORY AUTHORITIES TO DETERMINE NEXT STEPS REGARDING THE EXTENSION PHASE EVALUATING THE EFFECT OF ELAFIBRANOR ON CLINICAL OUTCOMES
* WILL PROVIDE UPDATED GUIDANCE ON ITS GLOBAL CORPORATE STRATEGY LATER IN THE YEAR
* WILL CONTINUE AS PLANNED WITH NIS4TM AND PHASE 3 PBC PROGRAMS
Source text for Eikon:
Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.